PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Net income growth of 42.50% while Biotechnology median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
0.99%
D&A growth of 0.99% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
66.71%
Working capital of 66.71% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-209.52%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
100.00%
Growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
51.97%
CFO growth of 51.97% while Biotechnology median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.